Inovio Pharmaceuticals (NASDAQ:INO) has priced its public offering of 17.7M common shares at $8.50/share, for expected gross proceeds of ~$150.5M.
Underwriters' over-allotment is an additional ~2.7M shares.
Net proceeds will be used for the development of its clinical pipeline, for general corporate purposes, including working capital.
Closing date is January 25.
Shares down 6% after-hours.
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2025 citybuzz
